» Articles » PMID: 31148900

Mechanisms of Hepatocellular Carcinoma Progression

Overview
Specialty Gastroenterology
Date 2019 Jun 1
PMID 31148900
Citations 112
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver. It is the second leading cause of cancer-related deaths worldwide, with a very poor prognosis. In the United States, there has been only minimal improvement in the prognosis for HCC patients over the past 15 years. Details of the molecular mechanisms and other mechanisms of HCC progression remain unclear. Consequently, there is an urgent need for better understanding of these mechanisms. HCC is often diagnosed at advanced stages, and most patients will therefore need systemic therapy, with sorafenib being the most common at the present time. However, sorafenib therapy only minimally enhances patient survival. This review provides a summary of some of the known mechanisms that either cause HCC or contribute to its progression. Included in this review are the roles of viral hepatitis, non-viral hepatitis, chronic alcohol intake, genetic predisposition and congenital abnormalities, toxic exposures, and autoimmune diseases of the liver. Well-established molecular mechanisms of HCC progression such as epithelial-mesenchymal transition, tumor-stromal interactions and the tumor microenvironment, cancer stem cells, and senescence bypass are also discussed. Additionally, we discuss the roles of circulating tumor cells, immunomodulation, and neural regulation as potential new mechanisms of HCC progression. A better understanding of these mechanisms could have implications for the development of novel and more effective therapeutic and prognostic strategies, which are critically needed.

Citing Articles

Navigating liver cancer: Precision targeting for enhanced treatment outcomes.

Jain A, Mishra A, Hurkat P, Shilpi S, Mody N, Jain S Drug Deliv Transl Res. 2025; .

PMID: 39847205 DOI: 10.1007/s13346-024-01780-x.


MPCD Index for Hepatocellular Carcinoma Patients Based on Mitochondrial Function and Cell Death Patterns.

Wang L, Zhao Z, Shu K, Ma M Int J Mol Sci. 2025; 26(1.

PMID: 39795978 PMC: 11719604. DOI: 10.3390/ijms26010118.


Exploring the therapeutic potential of natural compounds against hepatocellular carcinoma (HCC): a computational approach.

Ilyas S, Manan A, Choi Y, Lee D EXCLI J. 2025; 23():1440-1458.

PMID: 39790561 PMC: 11713998. DOI: 10.17179/excli2024-7970.


The role of histone lactylation genes in hepatocellular carcinoma prognostic models and their immune cell infiltration features: a comprehensive analysis of single-cell, spatial transcriptome, Mendelian randomization and experiment.

Luan S Discov Oncol. 2025; 16(1):29.

PMID: 39789404 PMC: 11717769. DOI: 10.1007/s12672-025-01775-1.


MicroRNAs and RNA-Binding Protein-Based Regulation of Bone Metastasis from Hepatobiliary Cancers and Potential Therapeutic Strategies.

Fagoonee S, Weiskirchen R Cells. 2024; 13(23).

PMID: 39682684 PMC: 11640337. DOI: 10.3390/cells13231935.


References
1.
Faouzi S, Lepreux S, Bedin C, Dubuisson L, Balabaud C, Bioulac-Sage P . Activation of cultured rat hepatic stellate cells by tumoral hepatocytes. Lab Invest. 1999; 79(4):485-93. View

2.
Thiery J . Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002; 2(6):442-54. DOI: 10.1038/nrc822. View

3.
Bralet M, Pichard V, Ferry N . Demonstration of direct lineage between hepatocytes and hepatocellular carcinoma in diethylnitrosamine-treated rats. Hepatology. 2002; 36(3):623-30. DOI: 10.1053/jhep.2002.35540. View

4.
Zhang Y, Bai X, Huang C . Hepatic stem cells: existence and origin. World J Gastroenterol. 2003; 9(2):201-4. PMC: 4611311. DOI: 10.3748/wjg.v9.i2.201. View

5.
Skinner H, Michaud D, Colditz G, Giovannucci E, Stampfer M, Willett W . Parity, reproductive factors, and the risk of pancreatic cancer in women. Cancer Epidemiol Biomarkers Prev. 2003; 12(5):433-8. View